Navigating Treatment Challenges in nAMD and DME
David Eichenbaum, MD, FASRS shares successful clinical experiences treating retinal diseases with second generation agents aflibercept 8 mg and faricimab, emphasizing improvements in visual acuity, anatomical features, and quality of life for patients.
EP. 2: Tolerance and Aggression: Achieving Improved Fluid Response
March 22nd 2024David Eichenbaum, MD, FASRS discusses his clinical experience in managing retinal fluid, emphasizing the need to dramatically reduce intraretinal fluid, highlighting different strategies of care that offer the best results for patients.
EP. 3: Clinical Perspectives Comparing Faricimab and Aflibercept 8mg
March 22nd 2024David Eichenbaum, MD, FASRS provides his clinical experience with faricimab and aflibercept 8 mg, highlighting the small and large changes that benefit a patient’s quality of life, such as improved visual anatomy or reducing the frequency of visits.
